Pharma Group, Under Pressure, Punches Back on PricesBy and
Industry responds to candidates’ plans, congressional scrutiny
Strategies include showing the high cost of drug failures
A top pharmaceutical lobbying group will begin a counteroffensive against scrutiny of industry pricing practices, responding to criticism from both major U.S. political parties in a contentious presidential election season.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.